Groupe d'Etude en Oncologie du Quebec

Title	Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
Protocole ID	EMERGE 402 (JZP712-402)
ClinicalTrials.gov ID	NCT04894591
Cancer Type(s)	Small Cells - Lung
Phase	Phase IV
Stage	Advanced or metastatic disease
Study Type	Other
Drug	Zepzelca
Institution	CISSS DE CHAUDIERE-APPALACHES HOTEL-DIEU DE LEVIS 143 rue Wolfe, Lévis, QC, G6V 3Z1
City
Principal Investigator	Dr. Danièle Marceau
Coordinator	Pierre Bédard 418-835-7121
Status	Recruiting
Activation Date
Eligibility Criteria	Patient has initiated or will be receiving Zepzelca treatment in line with the local Zepzelca prescribing information. Decision to initiate treatment with Zepzelca was made as per investigator's routine treatment practice prior to enrollment in the study. Patient, or a legally acceptable representative, signed the informed consent before any study-related activities are undertaken.
Exclusion Criteria	Patients who discontinued a prior Zepzelca treatment due to adverse events. Patient who received more than 2 cycles of Zepzelca treatment in their current treatment schedule. Patient received treatment with any investigational agent within 30 days prior to first Zepzelca infusion or plans to use another investigational agent while receiving Zepzelca.

Groupe d'étude en oncologie du Québec